Ascites Clinical Trial
Official title:
Local Modulated Electro-Hyperthermia in Combination With Traditional Chinese Medicine Versus Intraperitoneal Chemoinfusion in Treatment of Peritoneal Carcinomatosis With Malignant Ascites: A Phase II Randomized Trial
This trial studies efficacy and safety of combination of modulated electro-hyperthermia (mEHT) with Traditional Chinese Medicine (TCM) in treatment of peritoneal carcinomatosis with malignant ascites versus standard chemoinfusion (CDDP+5FU).
Conservative treatment of peritoneal carcinomatosis with malignant ascites (PCMA) is based on chemoinfusion with its inherent toxicity. There is a strong demand for a safe and non-toxic method of treatment of PCMA. The new technology of modulated electro-hyperthermia (mEHT) has proven efficacy in many advanced cancers with minimal side effects and synergy with Traditional Chinese Medicine (TCM). TCM has a long history of application at advanced cancer as a symptomatic treatment and enhancer of the general resistance of the organism. Shi Pi Decoction is supposed to be the optimum co-treatment of PCMA according to principles of TCM. Intraperitoneal chemoinfusion (IPCI) with cisplatin and fluorouracil is a widespread standard treatment of PCMA in China. This randomized II phase trial studies efficacy and safety of combination of mEHT with TCM in treatment of PCMA versus standard IPCI (CDDP+5FU). ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02891642 -
Liquid Biopsy With Immunomagnetic Beads Capture Technique for Malignant Cell Detection in Body Fluid
|
||
| Recruiting |
NCT00239096 -
Prevention of Decompensation in Liver Cirrhosis
|
Phase 4 | |
| Active, not recruiting |
NCT03973866 -
Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study)
|
N/A | |
| Completed |
NCT01349348 -
Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites
|
Phase 3 | |
| Terminated |
NCT01455246 -
Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis
|
Phase 2/Phase 3 | |
| Completed |
NCT01578226 -
Procalcitonin in Cirrhotic Patients at High Risk for Sepsis
|
N/A | |
| Terminated |
NCT00548366 -
Sodium Restriction in the Management of Cirrhotic Ascites
|
Phase 4 | |
| Recruiting |
NCT05025878 -
13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.
|
||
| Completed |
NCT03327688 -
Point-of-care Ultrasound in Finland
|
N/A | |
| Not yet recruiting |
NCT04550091 -
Role Of Multi-detector Computed Tomography In Differentiation Between Different Types Of Ascites
|
||
| Completed |
NCT01769040 -
Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis
|
Phase 4 | |
| Not yet recruiting |
NCT01716611 -
Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites
|
Phase 4 | |
| Recruiting |
NCT05700708 -
Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Refractory Ascites
|
||
| Recruiting |
NCT05511766 -
Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis
|
Phase 2/Phase 3 | |
| Completed |
NCT05013502 -
Empagliflozin in Diuretic Refractory Ascites
|
Phase 1 | |
| Not yet recruiting |
NCT06436807 -
PMCF Study of the CE-marked Drainova® ArgentiC Catheter
|
||
| Completed |
NCT03263598 -
Validation of Diagnostic Usefulness of the Random Urine Na/K Ratio for Replacement of 24hr Urine Na Excretion in Cirrhotic Patients With Ascites
|
||
| Completed |
NCT00907673 -
The Automated Fluid Shunt (AFS)in Chronic Congestive Heart Failure
|
N/A | |
| Terminated |
NCT00796861 -
Trial of Sunitinib for Refractory Malignant Ascites
|
Phase 2 | |
| Suspended |
NCT00511394 -
Acute Hemodynamics of Albumin Versus Normal Saline in Cirrhosis
|
N/A |